|
Sinoway Industrial Co.Ltd.
|
Product name: Ticargrelor
CAS No.：274693-27-5
Molecule Formula：C23H28F2N6O4S
Molecule Weight：522.57
Purity: 99.0%
Package: 25kg/drum
Description： White powder
Manufacture Standards：Enterprise Standard
|
TESTING ITEMS
|
SPECIFICATIONS
|
RESULTS
|
|
Appearance
|
White powder
|
Conforms
|
|
Identification
|
Meet the requirements
|
Conforms
|
|
Loss on drying
|
≤0.50%
|
0.08%
|
|
Residue on ignition
|
≤0.10%
|
0.05%
|
|
Heavy metals
|
≤10ppm
|
<10ppm
|
|
Assay
|
≥99.00%
|
99.60%
|
|
Conclusion:
The Product Conforms to Enterprise Standard.
|
|
Send Inquiry
|
|
Sinoway Industrial Co.Ltd.
|
|
Product name
|
Ticagrelor
|
|
CAS No.
|
274693-27-5
|
|
Molecular Formula
|
C23H28F2N6O4S
|
|
Molecular Weight
|
522.576
|
|
Quality Standard
|
99% up by HPLC
|
|
Appearance
|
White to off-white powder
|
|
ITEMS
|
SPECIFICATION
|
RESULTS
|
|
Appearance
|
White to off-white powder
|
Conforms
|
|
Optical rotation
|
-50。~ 60。
|
-53。
|
|
Identification
|
IR
|
Conforms
|
|
HPLC
|
Conforms
|
|
Isomers
|
TGD1≤0.15%
|
Undetected
|
|
TGD2≤0.15%
|
Undetected
|
|
TGE≤0.15%
|
Undetected
|
|
TG-16≤0.15%
|
Undetected
|
|
Related substance
|
De-ethoxyl of TG ≤ 0.15%
|
0.01%
|
|
Any single impurity ≤ 0.1%
|
0.05%
|
|
Total impurities ≤ 1.0%
|
0.10%
|
|
Residue on ignition
|
≤ 0.1%
|
0.08%
|
|
Loss on drying
|
≤ 0.5%
|
0.14%
|
|
Residual solvent
|
Ethyl ether <5000ppm
Acetone<5000ppm
Dichloromethane <600ppm
Ethyl acetate <5000ppm
Triethylamine <320ppm
Toluene<890ppm
Tetrahydrofuran <720ppm
Methanol<3000ppm
Ethanol<5000ppm
Acetonitrile<4 10ppm
hexane <290ppm
N-methyl pyrrolidone<530ppm
|
Undetected
Undetected
Undetected
73 ppm
Undetected
Undetected
Undetected
Undetected
Undetected
Undetected
Undetected
Undetected
|
|
Assay
|
99%-102%
|
100.5%
|
|
Conclusion
|
The result conforms to the enterprise standards.
|
Function of Ticagrelor
Today, with the continuous increase of acute coronary syndrome (ACS), antiplatelet therapy is still one of the important treatment measures for ACS. Ticagrelor is a novel cyclopentyltriazole pyrimidine (CPTP) oral antiplatelet drug with ATC code B01AC24. Ticagrelor is a non-prodrug that can act directly without hepatic metabolic activation, and binds reversibly to the P2Y12 ADP receptor. The results of the PLATO study showed that ticagrelor treatment for 12 months, without increasing major bleeding, further significantly reduced the risk of cardiovascular death/myocardial infarction/stroke composite endpoint events in ACS patients by 16%, and significantly Reduce cardiovascular death by 21%. The clinical efficacy and safety of ticagrelor have been validated and supported by the Platelet Inhibition and Patient Outcomes Outcomes Study (PLATO Study) and its multiple subgroups. Based on the benefits of ticagrelor treatment for ACS patients, guidelines in many countries state that ticagrelor is listed as the first-line recommendation. In the two authoritative guidelines of the European Society of Cardiology (ESC NSTE-ACS guidelines in 2011 and STEMI guidelines in 2012), it is pointed out that the use of clopidogrel in patients who cannot receive ticagrelor therapy is sufficient. Shows approval for the new drug to further reduce mortality.
|
Send Inquiry
|
Pharma Sources Insight June 2024: Globalization on the Go
